Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
J Pharmacol Exp Ther. 2014 Apr;349(1):138-54. doi: 10.1124/jpet.113.211904. Epub 2014 Jan 13.
J Pharmacol Exp Ther. 2014.
PMID: 24421319
mGlu(2) receptor-mediated modulation of conditioned avoidance behavior in rats.
Megens AA, Hendrickx HM, Hens KA, Talloen WJ, Lavreysen H.
Megens AA, et al. Among authors: hens ka.
Eur J Pharmacol. 2014 Mar 15;727:130-9. doi: 10.1016/j.ejphar.2014.01.044. Epub 2014 Jan 30.
Eur J Pharmacol. 2014.
PMID: 24486391
Item in Clipboard
JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
Atack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, Drinkenburg WH, Ahnaou A, Te Riele P, Langlois X, Hrupka B, De Haes P, Hendrickx H, Aerts N, Hens K, Wellens A, Vermeire J, Megens AA.
Atack JR, et al.
ACS Chem Neurosci. 2014 Oct 15;5(10):1005-19. doi: 10.1021/cn5001606. Epub 2014 Sep 24.
ACS Chem Neurosci. 2014.
PMID: 25203719
Item in Clipboard
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA, Ashton D, Vermeire JC, Vermote PC, Hens KA, Hillen LC, Fransen JF, Mahieu M, Heylen L, Leysen JE, Jurzak MR, Janssens F.
Megens AA, et al. Among authors: hens ka.
J Pharmacol Exp Ther. 2002 Aug;302(2):696-709. doi: 10.1124/jpet.102.034348.
J Pharmacol Exp Ther. 2002.
PMID: 12130734
Item in Clipboard
Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.
Andrés JI, Alcázar J, Alonso JM, Alvarez RM, Bakker MH, Biesmans I, Cid JM, De Lucas AI, Fernández J, Font LM, Hens KA, Iturrino L, Lenaerts I, Martínez S, Megens AA, Pastor J, Vermote PC, Steckler T.
Andrés JI, et al. Among authors: hens ka.
J Med Chem. 2005 Mar 24;48(6):2054-71. doi: 10.1021/jm049619s.
J Med Chem. 2005.
PMID: 15771448
Item in Clipboard
Cite
Cite